Amylyx(US:AMLX) Globenewswireยท2025-10-16 20:40Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Amylyx Pharmaceuticals, Inc. due to allegations of misleading statements regarding the commercial launch of their drug Relyvrio, which may have breached fiduciary duties to shareholders [2][3]. Group 1: Investigation Details - A class action complaint was filed against Amylyx on July 1, 2025, covering a class period from November 11, 2022, to November 8, 2023 [2]. - The complaint alleges that the board of directors made false and misleading statements about the success of the Relyvrio launch, including claims of "significant demand" that were not substantiated [3]. - Specific allegations include that the initial surge in demand for Relyvrio was temporary and that there was no meaningful growth potential among newly diagnosed ALS patients [3]. Group 2: Implications of Allegations - The complaint states that high discontinuation rates of Relyvrio were not disclosed, which undermined the drug's commercial viability and inflated the perceived potential for acquiring new patients [3]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and lacked a reasonable basis [3]. Group 3: Next Steps for Shareholders - Long-term stockholders of Amylyx are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [4].